A predominant cleaved form of pro-glucagon expressed in the intestine. GLP-1 [7-36]amide is promptly released from the gut after oral ingestion of a meal where it slows gastric emptying and exerts a powerful insulinotropic action leading to elevated serum insulin levels. GLP-1 [7-36] amide promotes satiety and reduces food intake in patients with diabetes mellitus type 2 and has been suggested to have therapeutic potential in the treatment of NIDDM. It has been reported that human pancreatic endocrine tumors contain molecular forms of GLP-1 which resemble those expressed in the small intestine, rather than in their tissue of origin.
Product Details
| Alternative Name: | GLP 1 (7-36) amide |
| |
| Sequence: | H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 |
| |
| MW: | 3297.7 |
| |
| Appearance: | Lyophilized solid. |
| |
| Solubility: | Soluble in water at 1mg/mL. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
GLP-1 Mediated Diuresis and Natriuresis Are Blunted in Heart Failure and Restored by Selective Afferent Renal Denervation: K. Katsurada, et al.; Cardiovasc. Diabetol.
19, 57 (2020),
Abstract;
Full Text
